Navigation Links
WellGen, Inc. and RFI Ingredients to Collaborate on Therapeutic Nutrition Opportunities

Partnership will develop proprietary medical food, functional food, and dietary supplement products with strong scientific roots and clinical support for burgeoning markets

North Brunswick, NJ and Blauvelt, NY (PRWEB) December 17, 2009 -- WellGen, Inc., a biotechnology company at the crossroads of foods and pharmaceuticals, and RFI Ingredients, a manufacturer of innovative natural ingredients, are pleased to announce the signing of a Memorandum of Understanding (MOU) covering a range of areas for cooperation. The new partnership is designed to enhance the business of both companies and bring exciting new natural products to the market. Products will have a strong base in science, solid clinical support, and affirmed GRAS (generally recognized as safe) status.
The MOU serves as a framework for collaboration on several high-growth opportunities: the creation of new medical foods for people with inflammation-related diseases for which there are major unmet needs; the creation of new dietary supplement and functional food products for consumer and health care professional markets; and the development and supply of natural ingredients with strong scientific and clinical support.

Commenting on the new relationship, Dr. Roddy Carter, president and chief executive officer of WellGen, states “the complementary skills of WellGen and RFI Ingredients will work synergistically to enhance the companies’ natural product offerings. Both companies have been acknowledged for their innovation and share a common interest in developing proprietary, high-quality products supported by strong clinical evidence. This collaboration will couple WellGen’s scientific and clinical know-how with RFI’s infrastructure and expertise in the natural products market. “

WellGen uses proprietary biotechnology methods and a deep understanding of natural products chemistry to develop and distinguish natural materials which they market in products for therapeutic purposes. WellGen is focused on inflammation-related disease for their medical food products and is currently working on a new medical food for diabetes.

RFI Ingredients, a manufacturer of natural ingredients has created a supply chain model and infrastructure that focuses on vertical integration and enhanced control over raw materials. RFI has an excellent track record in the development and marketing of branded ingredients. They have broad capabilities in ingredient supply and several proprietary ingredients in their portfolio of products. While RFI’s core business is ingredient supply, they also have two consumer brands, SoTru and PhytoRich.

“The proprietary research that WellGen has been conducting over the past four years combined with RFI’s innovative ingredients and superior approach to sourcing will provide a significant competitive advantage for both companies as we pursue parallel market opportunities.” stated RFI chief executive officer/ president and founder Jeff Wuagneux.

About RFI Ingredients
RFI Ingredients is a vertically-integrated manufacturer of innovative natural ingredients for the food, functional food and dietary supplement industries. The company, which was formed in 1989, specializes in the supply of quality ingredients (including certified-organic) and proprietary formulations. For more information about RFI Ingredients, please see

About WellGen, Inc.
WellGen, Inc., based in North Brunswick, N.J., is a biotechnology company at the crossroads of foods and pharmaceuticals. Using the science of nutrigenomics, the company has developed Alignomx™, a proprietary bioinformatics model that uses gene expression data to determine optimal therapeutic areas for WellGen’s pipeline of proprietary natural products. Through its in-house expertise in nutrigenomics and natural product chemistry, WellGen is developing proprietary medical foods and has additionally identified several opportunities in the functional food and beverage and dietary supplement markets. For more information about WellGen, Inc., please see

# # #

Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. WellGen, Inc. Names Nancy E. Rawson, Ph.D., Chief Scientific Officer
2. WellGen, Inc. Names Robert M. Hellauer as Chief Financial Officer
3. Dr. Roddy Carter Named President and Chief Executive Officer of WellGen, Inc.
4. WellGen, Inc. Launches Te Ame(TM) Nutritional Supplements With Proven Health Benefits of Proprietary Black Tea Extract
5. The Omega-3 Industry Leader, Croda Health Care, selects Neptune Technologies Ingredients for New Essentially Brand
6. Atrium completes the sale of its Active Ingredients and Specialty Chemicals division
7. Quantum dots and nanomaterials: Ingredients for better lighting and more reliable power
8. Microbia, Inc. Names Mike Doyle as Senior Vice President and General Manager, Nutrition Ingredients
9. The Global Active Pharmaceutical Ingredients (API) Market: A Frost & Sullivan Briefing on Changing Dynamics
10. Ajinomoto Food Ingredients LLC Expands Capabilities
11. InVitrias Better Ingredients for Better Media to be Showcased at BPI 09
Post Your Comments:
Related Image:
WellGen, Inc. and RFI Ingredients to Collaborate on Therapeutic Nutrition Opportunities 
(Date:10/11/2017)... 11, 2017  VMS BioMarketing, a leading provider of patient ... Clinical Nurse Educator (CNE) network, which will launch this week. ... among health care professionals to enhance the patient care experience ... and other health care professionals to help women who have ... ...
(Date:10/11/2017)... ... 11, 2017 , ... Disappearing forests and increased emissions are the main causes ... each year. Especially those living in larger cities are affected by air pollution related ... the most pollution-affected countries globally - decided to take action. , “I knew I ...
(Date:10/11/2017)... Bay, Florida (PRWEB) , ... October 11, 2017 ... ... and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel ... (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the cell ...
(Date:10/10/2017)... (PRWEB) , ... October 10, ... ... development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed ... targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer ... Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - ... to grow from USD 14.30 Billion in 2017 to USD 31.75 Billion ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
Breaking Biology News(10 mins):